PE20131165A1 - 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT - Google Patents

2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT

Info

Publication number
PE20131165A1
PE20131165A1 PE2013000530A PE2013000530A PE20131165A1 PE 20131165 A1 PE20131165 A1 PE 20131165A1 PE 2013000530 A PE2013000530 A PE 2013000530A PE 2013000530 A PE2013000530 A PE 2013000530A PE 20131165 A1 PE20131165 A1 PE 20131165A1
Authority
PE
Peru
Prior art keywords
fluorine substituted
antiviral treatment
halogen
alkyl
nucleosid
Prior art date
Application number
PE2013000530A
Other languages
Spanish (es)
Inventor
Aesop Chop
Choung Kim
Adrian Ray
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/885,917 external-priority patent/US7973013B2/en
Priority claimed from US13/050,820 external-priority patent/US8455451B2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20131165A1 publication Critical patent/PE20131165A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (IV), DONDE R1 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ENTRE OTROS; R2 ES HALOGENO; R3, R4 Y R5 SON H, HALOGENO, N3, CN, NO2, ENTRE OTROS; n ES 0 A 2; R7 ES H, C(=O)R11, S(O)R11, ENTRE OTROS; R8 ES HALOGENO, N(R11)OR11, N3, NO, ENTRE OTROS; R9 ES H, HALOGENO, NO, NO2, ENTRE OTROS; R11 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (a), (b), (c), ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ARN POLIMERASA DEPENDIENTE DE ARN DEL VIRUS DE LA HEPATITIS CREFERRING TO A HETEROCYCLIC COMPOUND OF FORMULA (IV), WHERE R1 IS C1-C8 ALKYL, C2-C8 ALKENYL, C2-C8 ALKYL, AMONG OTHERS; R2 IS HALOGEN; R3, R4 AND R5 ARE H, HALOGEN, N3, CN, NO2, AMONG OTHERS; n IS 0 A 2; R7 IS H, C (= O) R11, S (O) R11, AMONG OTHERS; R8 IS HALOGEN, N (R11) OR11, N3, NO, AMONG OTHERS; R9 IS H, HALOGEN, NO, NO2, AMONG OTHERS; R11 IS H, C1-C8 ALKYL, C2-C8 ALKYL, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: (a), (b), (c), AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF THE RNA-DEPENDENT RNA POLYMERASE OF THE HEPATITIS C VIRUS

PE2013000530A 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT PE20131165A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/885,917 US7973013B2 (en) 2009-09-21 2010-09-20 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US13/050,820 US8455451B2 (en) 2009-09-21 2011-03-17 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
PE20131165A1 true PE20131165A1 (en) 2013-10-14

Family

ID=47748238

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2013000530A PE20131165A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE2017001530A PE20171624A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE2022003082A PE20230684A1 (en) 2010-09-20 2011-03-22 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS AS RNA POLYMERASE INHIBITORS

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2017001530A PE20171624A1 (en) 2010-09-20 2011-03-22 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE2022003082A PE20230684A1 (en) 2010-09-20 2011-03-22 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS AS RNA POLYMERASE INHIBITORS

Country Status (21)

Country Link
EP (1) EP2619206A1 (en)
JP (4) JP2013538230A (en)
KR (1) KR101879887B1 (en)
CN (1) CN103108876A (en)
AP (1) AP3699A (en)
AU (1) AU2011306066B2 (en)
BR (1) BR112013008017A2 (en)
CA (1) CA2807496C (en)
CL (1) CL2013000727A1 (en)
CO (1) CO6680669A2 (en)
CR (1) CR20130172A (en)
EA (1) EA026523B1 (en)
EC (1) ECSP13012560A (en)
IL (1) IL225221A0 (en)
MA (1) MA34593B1 (en)
MX (1) MX2013003179A (en)
NZ (1) NZ608070A (en)
PE (3) PE20131165A1 (en)
SG (1) SG188223A1 (en)
WO (1) WO2012039791A1 (en)
ZA (1) ZA201301042B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2937350T3 (en) 2008-04-23 2018-06-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
PL2480559T3 (en) 2009-09-21 2013-11-29 Gilead Sciences Inc Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
CN103052631B (en) 2010-07-22 2015-11-25 吉里德科学公司 Be used for the treatment of method and the compound of the infection of paramyxovirus coe virus
TW201701876A (en) 2010-12-20 2017-01-16 吉李德科學股份有限公司 Methods for treating HCV
TW201329096A (en) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
UA119050C2 (en) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
TWI678369B (en) 2014-07-28 2019-12-01 美商基利科學股份有限公司 Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
CN104230985B (en) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 Preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate
TWI687432B (en) 2014-10-29 2020-03-11 美商基利科學股份有限公司 Methods for treating filoviridae virus infections
EA201791460A1 (en) 2014-12-26 2017-12-29 Эмори Юниверсити N4-HYDROXYCYTIDINE AND RELATED DERIVATIVES AND OPTIONS FOR ANTI-VIRUS APPLICATION
DK3785717T3 (en) 2015-09-16 2022-03-21 Gilead Sciences Inc PROCEDURES FOR THE TREATMENT OF CORONAVIRIDAE INFECTIONS
JP6824434B2 (en) 2017-03-14 2021-02-03 ギリアード サイエンシーズ， インコーポレイテッド How to treat feline coronavirus infection
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (en) 2017-07-11 2024-03-08 吉利德科学公司 Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections
BR122022008466B1 (en) 2017-12-07 2023-12-05 Emory University USE OF A COMPOUND
CN114641299A (en) 2020-01-27 2022-06-17 吉利德科学公司 Methods for treating SARS CoV-2 infection
AU2021234308C1 (en) 2020-03-12 2024-02-22 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (en) 2020-05-29 2022-02-01 美商基利科學股份有限公司 Remdesivir treatment methods
CA3187821A1 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
TW202233204A (en) 2020-08-27 2022-09-01 美商基利科學股份有限公司 Compounds and methods for treatment of viral infections
EP4320128A1 (en) 2022-03-02 2024-02-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US20230338409A1 (en) * 2022-04-25 2023-10-26 Miracure Biotechnology Limited Nucleoside drugs for the treatment or prevention of coronavirus infection and their uses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (en) 1990-06-13 1996-04-16 Arnold Glazier PHOSPHORIC DRUGS.
DE69129650T2 (en) 1990-09-14 1999-03-25 Acad Of Science Czech Republic Precursor of phosphonates
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (en) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1427722A (en) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 Method for treatment or prevention of flavivirus infections using nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN1646141B (en) 2000-10-18 2014-06-25 吉利德制药有限责任公司 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
MY134070A (en) 2001-01-22 2007-11-30 Isis Pharmaceuticals Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2005536440A (en) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド Methods and compositions for the treatment of flaviviruses and pestiviruses using nucleosides modified at the 4 'position
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
BR122018015050B1 (en) * 2003-05-30 2021-07-13 Gilead Pharmasset Llc PHOSPHATE NUCLEOSIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION
ES2725457T3 (en) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparation of ribofuranosyl pyrimidines and 2'fluoro-2'-alkyl-substituted or other optionally substituted purines and their derivatives
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
CN101043893A (en) * 2004-10-21 2007-09-26 默克公司 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
JP5116687B2 (en) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト Pyrrolo [2,1-f] [1,2,4] triazin-4-ylamine IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2008085508A2 (en) 2007-01-05 2008-07-17 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
CN101611046A (en) 2007-01-12 2009-12-23 拜奥克里斯特制药公司 Antiviral nucleoside analogs
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US8242085B2 (en) 2007-05-10 2012-08-14 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer
PL2937350T3 (en) 2008-04-23 2018-06-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PE20161067A1 (en) * 2009-02-10 2016-10-23 Gilead Sciences Inc CARBA-NUCLEOSIDIC ANALOGS FOR ANTIVIRAL TREATMENT
ME02656B (en) * 2009-09-21 2017-06-20 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Also Published As

Publication number Publication date
PE20230684A1 (en) 2023-04-21
AP3699A (en) 2016-05-31
CL2013000727A1 (en) 2013-08-23
AU2011306066B2 (en) 2015-01-29
CO6680669A2 (en) 2013-05-31
IL225221A0 (en) 2013-06-27
EP2619206A1 (en) 2013-07-31
CA2807496A1 (en) 2012-03-29
MX2013003179A (en) 2013-04-24
CR20130172A (en) 2013-05-29
NZ608070A (en) 2015-11-27
JP2019014726A (en) 2019-01-31
CN103108876A (en) 2013-05-15
CA2807496C (en) 2019-01-22
PE20171624A1 (en) 2017-11-02
WO2012039791A1 (en) 2012-03-29
BR112013008017A2 (en) 2016-06-14
AP2013006767A0 (en) 2013-03-31
ECSP13012560A (en) 2013-06-28
SG188223A1 (en) 2013-04-30
KR101879887B1 (en) 2018-07-18
JP2013538230A (en) 2013-10-10
EA201390141A1 (en) 2013-09-30
AU2011306066A1 (en) 2013-02-28
EA026523B1 (en) 2017-04-28
JP6475280B2 (en) 2019-02-27
JP2017119726A (en) 2017-07-06
ZA201301042B (en) 2014-07-30
KR20130110168A (en) 2013-10-08
JP2016074732A (en) 2016-05-12
MA34593B1 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
PE20131165A1 (en) 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE20120995A1 (en) 2'-FLUORINE SUBSTITUTED CARBA-NUCLEOSID ANALOGS FOR ANTIVIRAL TREATMENT
PE20120257A1 (en) CARBA-NUCLEOSIDIC ANALOGS FOR ANTIVIRAL TREATMENT
CO6331439A2 (en) 1-2 BICYCLES PIRIMIDINONA CARBOXAMIDA AS INHIBITORS OF THE INTEGRESS OF THE HUMAN IMMUNODEFICIENCY VIRUS
CR20150085A (en) NEW 6-AMINO ACID-HETEROARILDIHYDROPIRMIDINDAS FOR THE TREATMENT AND PROFILAXIS OF HEPATITIS B VIRUS INFECTION
PE20140608A1 (en) REPLACED NUCLEOTIDE ANALOGS
PE20140522A1 (en) DERIVATIVES OF NUCLEOSIDES 2'- SUBSTITUTED AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES
PE20171155A1 (en) METHODS AND COMPOUNDS TO TREAT VIRAL PARAMYXOVIRIDAE INFECTIONS
EA201592126A1 (en) 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
EA201590943A1 (en) SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES
MA37712B1 (en) Macrocyclic inhibitors of flaviviridae virus
PH12015501473A1 (en) Novel antiviral agents against hbv infection
EA201000100A1 (en) HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS
PE20191461A1 (en) AMIDA COMPOUNDS FOR THE TREATMENT OF HIV
PE20142456A1 (en) OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF PI3Ks
AR090760A1 (en) BENZOTIAZOL COMPOUNDS AND THEIR USE AGAINST HIV VIRUS
PE20211472A1 (en) DERIVATIVES OF 2- (PHENYLOXY OR PHENYLTHIUM) PYRIMIDINE AS HERBICIDES
CR10136A (en) ANTIVIRAL NUCLEOSIDS
PE20091236A1 (en) PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
AR077977A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
RU2010140627A (en) Pyrrolidine derivatives
UY31538A1 (en) VIRICA POLYMERASE INHIBITORS
CO6382185A2 (en) ANTIVIRAL NUCLEOSID COMPOUNDS
EA201600241A1 (en) SUBSTITUTED (2R, 3R, 5R) -3-HYDROXY- (5-PYRIMIDIN-1-IL) TETRAHYDROFURAN-2-ILMETYL ARIL PHOSPHORAMIDATES
EA201591328A1 (en) HETEROCYCLED SUBSTITUTED TETRICYCLIC COMPOUNDS AND METHODS OF THEIR USE FOR THE TREATMENT OF VIRAL DISEASES

Legal Events

Date Code Title Description
FG Grant, registration